Project Grant R41TR006349
Award Date 8/17/26
Completion Date 8/16/27
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Huntsville, AL 35806, USA
Similar Awards
- The National Center for Advancing Translational Sciences awarded Intero Biosystems Inc. $1.046897 million in project grant funding on July 1, 2026, under CFDA 93.350. Intero Biosystems will develop a stem cell-derived human intestinal organoid platform for drug discovery and preclinical testing. The platform incorporates multiple cell types of the native intestine to model both normal intestinal function and disease processes. Phase II work will scale production methods and validate assay...
- The National Center for Advancing Translational Sciences (NCATS) awarded Syntr Health Technologies, Inc., $2,050,527 on September 25, 2025, under the NCATS program (CFDA 93.350) to automate an FDA-cleared CD-microfluidic platform for rapid tissue microsizing. Syntr Health will develop device automation for its SYNTRFUGE system and SYNTRFPU360 platform to streamline tissue processing and dissociation. The technology processes multiple tissue types—including kidney, liver, brain, and breast cancer...
- The National Center for Advancing Translational Sciences awarded Goeppert LLC, a Philadelphia-based small disadvantaged business, $350,000 on July 1, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop NANO-PAVE, a nanopore-based platform for assessing adeno-associated virus (AAV) capsid quality in gene therapy manufacturing. NANO-PAVE addresses a critical bottleneck in AAV clinical translation: current quality-control assays (ELISA, ddPCR, analytical...
- Federal Grant Award Summary Intero Biosystems Inc. received a $349,952 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 20, 2025, with a completion date of June 19, 2026. In collaboration with the University of Michigan, the awardee is developing and validating a novel stem cell-derived human intestinal organoid (HIO) screening platform designed to improve preclinical drug testing and reduce the current 90% failure rate of drug...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $180,000 to CFD Research Corporation on September 5, 2026, under the National Center for Advancing Translational Sciences program (CFDA 93.350) to develop FERTILICHIP, an innovative fallopian tube-on-chip microfluidic model for women's reproductive health research. FERTILICHIP will be the first comprehensive, vascularized human fallopian tube in vitro model system incorporating four key...
- The federal Project Grant award of $350,000 was provided by the National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, to Vivosphere LLC in Auburn, AL. The funding will support the development of "Vivospheres", which are tissue-engineered spheroidal models for high-throughput screening. The project aims to establish Vivospheres as a more consistent and flexible 3D cell culture system compared to traditional self-aggregation methods, enabling...
- The National Center for Advancing Translational Sciences at the National Institutes of Health, under the Department of Health and Human Services, awarded $957,707 to Cytoterra Inc. on July 1, 2026, through the NCATS Program (CFDA 93.350). Cytoterra will develop and validate a high-throughput genomic integrity assessment platform for allogeneic cell therapies. The project combines genomic proximity mapping technology with whole exome sequencing in a platform called Cytoterra Plus to detect...
- The National Center for Advancing Translational Sciences awarded Aigene Inc. $349,890 on July 1, 2026, under the NCATS program (CFDA 93.350) to develop a novel home and laboratory system for improved cell-free DNA screening and monitoring using transrenal DNA. The project addresses limitations in blood cell-free DNA analysis for diagnostic and monitoring applications including perinatal screening, transplant monitoring, cancer therapy selection, and multiple-cancer early detection. The system...
- The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded The Broad Institute, Inc. $436,250 on May 1, 2026, under the NCATS program (CFDA 93.350) to develop and validate the RAPID (Rare Disease Analysis Through Pooled Image-Based Identification of Drugs) platform for drug repurposing in rare disorders. The Broad Institute will develop a massively parallel screening platform that integrates pooled optical variant identification,...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded The Trustees of Princeton University $164,000 on July 1, 2026, under the National Center for Advancing Translational Sciences program (CFDA 93.350). The award funds investigation of understudied rare disease genes associated with heterotaxy, a rare congenital disorder characterized by mispositioned internal organs and cardiac malformations. Using zebrafish models, the project will assess the...